<ARTICLE> 5 <LEGEND> THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE FINANCIAL STATEMENTS OF BIOSHIELD TECHNOLOGIES, INC. FOR THE 9 MONTHS ENDED MARCH 31, 1999 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS. </LEGEND> <PERIOD-TYPE> 9-MOS <FISCAL-YEAR-END> JUN-30-1999 <PERIOD-START> JUL-01-1998 <PERIOD-END> MAR-31-1999 <CASH> 2,868,543 <SECURITIES> 91,000 <RECEIVABLES> 157,254 <ALLOWANCES> 30,000 <INVENTORY> 100,350 <CURRENT-ASSETS> 3,240,721 <PP&E> 154,464 <DEPRECIATION> 34,123 <TOTAL-ASSETS> 3,476,512 <CURRENT-LIABILITIES> 173,198 <BONDS> 0 <PREFERRED-MANDATORY> 0 <PREFERRED> 0 <COMMON> 6,480,738 <OTHER-SE> (3,177,424) <TOTAL-LIABILITY-AND-EQUITY> 3,476,512 <SALES> 286,182 <TOTAL-REVENUES> 286,182 <CGS> 120,726 <TOTAL-COSTS> 610,436 <OTHER-EXPENSES> 1,148,203 <LOSS-PROVISION> 18,095 <INTEREST-EXPENSE> 16,960 <INCOME-PRETAX> (1,536,020) <INCOME-TAX> 0 <INCOME-CONTINUING> (1,536,020) <DISCONTINUED> 0 <EXTRAORDINARY> 0 <CHANGES> 0 <NET-INCOME> (1,536,020) <EPS-PRIMARY> (0.27)<F1> <EPS-DILUTED> 0 <FN> <F1>DILUTED LOSS PER COMMON SHARE IS NOT DISCLOSED BECAUSE THE EFFECT OF THE EXCHANGE OR EXERCISE OF COMMON STOCK EQUIVALENTS WOULD BE ANTIDILUTIVE </FN>